Related Experiment Video
Updated: Jan 9, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Paeoniflorin as a natural mixed-type CYP1B1 inhibitor: enzyme kinetics, molecular simulation and drug-likeness
Liwei Jia1, Jinyue Lu1, Lei Zhou1
1School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, P. R. China.
Abstract:
Paeoniflorin (PF), a monoterpene glycoside from Paeonia species, is known for its antioxidant and anti-inflammatory properties. This study investigated its inhibitory activity against cytochrome P450 1B1 (CYP1B1), a procarcinogen-activating enzyme overexpressed in multiple tumours. Fluorescence-based assays showed dose-dependent inhibition of CYP1B1 by PF, with an IC50 of 0.83 ± 0.17 mM. Kinetic analysis revealed a mixed-type mechanism, suggesting PF binds both free enzyme and enzyme-substrate complex. Molecular docking indicated interactions with active site residues, supported by 100 ns molecular dynamics simulations confirming complex stability. ADMET predictions suggested low toxicity and favourable drug-likeness, though limited oral bioavailability. Collectively, PF is identified as a selective, natural CYP1B1 inhibitor, offering potential for cancer chemoprevention. These findings provide mechanistic insight into CYP1B1 inhibition by monoterpenoids and support future structure-activity relationship (SAR) development.
More Related Videos
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...